Brain-derived Neurotrophic Factor (BDNF) Changes in Rodent Models of Schizophrenia Induced by Ketamine: a Systematic Review

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2025 Feb 20

PMID 39976721

Authors

Atefeh Motamedi-Manesh

Mahdieh Farzin Asanjan

Hamed Fallah

Shahrzad Gharibian

Alireza Taghavi

Zahra Haghighi Poode

Shahin Akhondzadeh

Salar Vaseghi

Affiliations

Soon will be listed here.

Abstract

Schizophrenia is a severe neuropsychiatric disorder ranking among the top ten global disability causes. In rodents, sub-chronic or chronic ketamine treatment is used for the induction of schizophrenia. Ketamine affects the function of brain-derived neurotrophic factor (BDNF), the most important neurotrophin involved in the pathophysiology of different neuropsychiatric disorders. The present systematic review aimed to investigate BDNF changes in rodent studies used ketamine-induced schizophrenia. PubMed electronic database was searched and 44 articles were found. After removal of unrelated articles, 17 articles were selected. The results showed a wide range of inconsistent changes in BDNF levels. We found that sub-chronic and chronic ketamine treatment in rats decreased BDNF or had no effect. Sub-chronic and chronic ketamine treatment in mice only decreased BDNF. However, increased BDNF was commonly observed following acute ketamine treatment. These results showed the possible role of species and the duration of treatment. Also, sex can also be involved in BDNF changes because one study showed inconsistent BDNF changes in male and female rats. In conclusion, we found that ketamine's effects may depend on factors such as duration of administration, sex, and species. Therefore, the wide range of BDNF changes may be related to high variability in methods. Because of this variability, there is currently no standardized method for using ketamine as a rodent model for schizophrenia. Further research is needed to establish a standardized pharmacological model of schizophrenia using ketamine treatment.

References

Abbasi N, Mirabzadeh Y, Khesali G, Ebrahimkhani Z, Karimi H, Vaseghi S . Chronic REM sleep deprivation leads to manic- and OCD-related behaviors, and decreases hippocampal BDNF expression in female rats. Psychopharmacology (Berl). 2024; 241(7):1345-1363. DOI: 10.1007/s00213-024-06566-0. View

Ahmed H, Abdel-Sattar S, Zaky H . Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway. Naunyn Schmiedebergs Arch Pharmacol. 2018; 391(12):1327-1338. DOI: 10.1007/s00210-018-1552-y. View

Angelucci F, Ricci V, Gelfo F, Martinotti G, Brunetti M, Sepede G . BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure. Brain Cogn. 2013; 84(1):118-22. DOI: 10.1016/j.bandc.2013.11.012. View

Autry A, Adachi M, Nosyreva E, Na E, Los M, Cheng P . NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011; 475(7354):91-5. PMC: 3172695. DOI: 10.1038/nature10130. View

Autry A, Monteggia L . Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012; 64(2):238-58. PMC: 3310485. DOI: 10.1124/pr.111.005108. View

Becker A, Grecksch G, Schwegler H, Roskoden T . Expression of mRNA of neurotrophic factors and their receptors are significantly altered after subchronic ketamine treatment. Med Chem. 2008; 4(3):256-63. DOI: 10.2174/157340608784325124. View

Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G . Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(4):687-700. DOI: 10.1016/S0278-5846(03)00080-0. View

Ben-Azu B, Aderibigbe A, Ajayi A, Eneni A, Umukoro S, Iwalewa E . Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice. Brain Res Bull. 2018; 139:292-306. DOI: 10.1016/j.brainresbull.2018.03.006. View

Ben-Azu B, Uruaka C, Ajayi A, Jarikre T, Nwangwa K, Chilaka K . Reversal and Preventive Pleiotropic Mechanisms Involved in the Antipsychotic-Like Effect of Taurine, an Essential β-Amino Acid in Ketamine-Induced Experimental Schizophrenia in Mice. Neurochem Res. 2022; 48(3):816-829. DOI: 10.1007/s11064-022-03808-5. View

10.

Borella V, Seeman M, Cordeiro R, Vieira Dos Santos J, de Souza M, Nunes de Sousa Fernandes E . Gender and estrous cycle influences on behavioral and neurochemical alterations in adult rats neonatally administered ketamine. Dev Neurobiol. 2015; 76(5):519-32. DOI: 10.1002/dneu.22329. View

11.

Chen S, Lee S, Chang Y, Chen S, Chu C, Tzeng N . Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmune Pharmacol. 2012; 7(3):656-64. PMC: 3611097. DOI: 10.1007/s11481-012-9382-z. View

12.

Choi M, Lee S, Park M, Kim Y, Son H . Ketamine induces brain-derived neurotrophic factor expression via phosphorylation of histone deacetylase 5 in rats. Biochem Biophys Res Commun. 2017; 489(4):420-425. DOI: 10.1016/j.bbrc.2017.05.157. View

13.

Cohen S, Gabel H, Hemberg M, Hutchinson A, Sadacca L, Ebert D . Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron. 2011; 72(1):72-85. PMC: 3226708. DOI: 10.1016/j.neuron.2011.08.022. View

14.

de Araujo F, Chaves Filho A, Nunes A, de Oliveira G, Gomes P, Vasconcelos G . Involvement of anti-inflammatory, antioxidant, and BDNF up-regulating properties in the antipsychotic-like effect of the essential oil of Alpinia zerumbet in mice: a comparative study with olanzapine. Metab Brain Dis. 2021; 36(8):2283-2297. DOI: 10.1007/s11011-021-00821-5. View

15.

Derakhshanian S, Zhou M, Rath A, Barlow R, Bertrand S, DeGraw C . Role of Ketamine in the Treatment of Psychiatric Disorders. Health Psychol Res. 2022; 9(1):25091. PMC: 8801551. DOI: 10.52965/001c.25091. View

16.

Di Carlo P, Punzi G, Ursini G . Brain-derived neurotrophic factor and schizophrenia. Psychiatr Genet. 2019; 29(5):200-210. PMC: 7386257. DOI: 10.1097/YPG.0000000000000237. View

17.

Fan J, Tang Z, Wang S, Lei S, Zhang B, Tian S . Ketamine enhances novel object recognition memory reconsolidation via the BDNF/TrkB pathway in mice. Physiol Behav. 2021; 242:113626. DOI: 10.1016/j.physbeh.2021.113626. View

18.

Favalli G, Li J, Belmonte-de-Abreu P, Wong A, Daskalakis Z . The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res. 2011; 46(1):1-11. DOI: 10.1016/j.jpsychires.2011.09.022. View

19.

Gama C, Canever L, Panizzutti B, Gubert C, Stertz L, Massuda R . Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia. Schizophr Res. 2012; 141(2-3):162-7. DOI: 10.1016/j.schres.2012.08.002. View

20.

Gholizadeh N, Dalimi A, Ghaffarifar F, Nader-Mohammadi M, Molavi P, Dadkhah M . Berberine improves inhibitory avoidance memory impairment of Toxoplasma gondii-infected rat model of ketamine-induced schizophrenia. BMC Complement Med Ther. 2023; 23(1):303. PMC: 10469906. DOI: 10.1186/s12906-023-04107-4. View